Table 3.
CD42b glycoprotein expression at prostate adenocarcinoma, benign prostatic hyperplasia, and non-malignant adjacent tissue samples.
| Number | Parameters | Control X ± SD |
PCa X ± SD |
Control X ± SD |
BPH X ± SD |
|---|---|---|---|---|---|
| 1 | CD42bT | 86.98 ± 5.23 | 76.07 ± 12.95 | 86.98 ± 5.23 | 77.75 ± 17.37 |
| p values | 0.113 | 0.209 | |||
| 2 | CD42b+ | 26.24 ± 0.62 ** | 38.39 ± 11.23 ** | 26.24 ± 0.62 | 38.06 ± 17.43 |
| p values | 0.001 | 0.061 | |||
| 3 | CD42b- | 73.14 ± 0.08 ** | 59.26 ± 12.02 ** | 73.14 ± 0.08 * | 59.97 ± 17.15 * |
| p values | 0.000 | 0.038 | |||
Legend: X, obtained results mean; SD, standard deviation; PCa, prostate adenocarcinoma; BPH, benign prostatic hyperplasia; CD42b T, total CD42b glycoprotein expression; ** p ≤ 0.01 and * p < 0.05 represent statistically significant differences between controls and experimental samples made by independent t test.